Sarah Cannon Research Institute (SCRI) — Nashville, Tennessee

Sarah Cannon Research Institute (SCRI) is a clinical research site located in Nashville, Tennessee, United States 37203.

Crixeo Health Trust Score: 79/100 (FAIR). This profile has not yet been claimed by the site owner.

Sarah Cannon Research Institute (SCRI) has participated in 12 clinical trials with 4 currently active.

Therapeutic areas: Advanced Cancer, Solid Tumor, Primary Myelofibrosis.

Sponsors: M.D. Anderson Cancer Center, CTI BioPharma, Xadcera Biopharmaceutical (Suzhou) Co., Ltd..

Sponsor Feasibility Report

Trust Score: 79/100. Verification status: Crixeo Accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Sarah Cannon Research Institute (SCRI)?

Sarah Cannon Research Institute (SCRI) has a Crixeo Trust Score of 79/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Sarah Cannon Research Institute (SCRI) conducted?

Sarah Cannon Research Institute (SCRI) has 12 clinical trials on record, with 4 currently active. Their work covers Advanced Cancer, Solid Tumor, Primary Myelofibrosis.

Is Sarah Cannon Research Institute (SCRI) accredited by Crixeo Health?

Yes — Sarah Cannon Research Institute (SCRI) holds Crixeo Accreditation, the quality standard for clinical research sites. Accredited sites have verified compliance documents, strong patient reviews, and sponsor transparency.

Can I submit a review or complaint about Sarah Cannon Research Institute (SCRI)?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.